56Curated trials
Enterprise Evidence Report · NR-REPORT-V2.0
Romania
Neuroscience Intelligence
Romania neuroscience evidence report: current clinical, research, institution and source-linked intelligence.
Evidence rank #39 of 50 · Data maturity A · Research score 29.6 · Data confidence 100.0 / 100 · Snapshot 2026-10-12 03:34 UTC.
9Recruiting trials
18Publications
18Institutions
Executive interpretation
Romania ranks #39 in the current NeuroRisk evidence-ranked market layer. This ranking summarizes indexed clinical, publication and institution evidence; it is not a probability of commercial success and not an investment recommendation.
Methodology status
Methodology NR-REPORT-V2.0. No synthetic ML confidence is presented as scientific probability. Counts and source links below are tied to the generation snapshot.
Methodology →Leading sponsors
Eli Lilly and Company40 recruiting
AbbVie30 recruiting
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.30 recruiting
Hoffmann-La Roche31 recruiting
Merck Sharp & Dohme LLC33 recruiting
Novo Nordisk A/S30 recruiting
Novartis Pharmaceuticals21 recruiting
Celgene20 recruiting
Boehringer Ingelheim20 recruiting
Eisai Limited20 recruiting
Disease activity
Epilepsy11trials
Parkinsons10trials
Alzheimers6trials
Multiple Sclerosis5trials
Stroke3trials
Schizophrenia3trials
Other Neurology2trials
Depression2trials
Neuromuscular1trials
Migraine Headache1trials
Research institutions
Victor Babeș University of Medicine and Pharmacy TimișoaraOpenAlexlinked institution
University of BucharestOpenAlexlinked institution
Iuliu Hațieganu University of Medicine and PharmacyOpenAlexlinked institution
Romanian AcademyOpenAlexlinked institution
Grigore T. Popa University of Medicine and PharmacyOpenAlexlinked institution
Institute of Oncology Prof. Dr. Ion ChiricutaOpenAlexlinked institution
National School of Public Health, Management and Professional DevelopmentOpenAlexlinked institution
Universitatea Națională de Știință și Tehnologie Politehnica BucureștiOpenAlexlinked institution
National Institute for Laser Plasma and Radiation PhysicsOpenAlexlinked institution
Bucharest Emergency University HospitalOpenAlexlinked institution
Clinical evidence trail
NCT07011732A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)RECRUITING
NCT06966700A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)RECRUITING
NCT06887192A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease PsychosisRECRUITING
NCT06744920A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia GravisRECRUITING
NCT05980949Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)RECRUITING
NCT05973773REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)ACTIVE_NOT_RECRUITING
NCT05239728A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)ACTIVE_NOT_RECRUITING
NCT05123703A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)ACTIVE_NOT_RECRUITING
NCT04736706A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)ACTIVE_NOT_RECRUITING
NCT06756711Combination of Supplements for Treating Autistic Spectrum DisorderENROLLING_BY_INVITATION
NCT05798520A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)COMPLETED
Research evidence trail
PUBMEDNeuroimaging anxious children and adolescents before and after cognitive behavioral therapy: a systematic review.2026-12-01
PUBMEDA ketamine/methionine exposure paradigm, alone or combined with Lactobacillus rhamnosus GG, assessing schizophrenia-relevant behavioral, oxidative stress, and molecular endpoints in adult zebrafish.2026-11-01
PUBMEDMeta-Analysis: Parenting Children and Adolescents With Attention-Deficit/Hyperactivity Disorder Compared to Healthy Controls.2026-10-01
PUBMEDPatterns of onset and progression of psychoses induced by psychoactive substance use.2026-10-01
PUBMEDReal-World Effectiveness and Safety of Anti-CGRP Monoclonal Antibodies in the Prevention of High-Frequency Episodic and Chronic Migraine in Romania-A Multicenter Retrospective Observational Study.2026-09-20
PUBMEDRNA-Based Therapeutics in Genetic Neurodevelopmental Disorders: Bridging Molecular Genetics and Precision Medicine.2026-08-28
PUBMEDCerebral Venous Sinus Thrombosis Revealing ALK-Positive Anaplastic Large-Cell Lymphoma in a Patient with Inherited Thrombophilia and Concomitant Infection: Case Report and Narrative Review.2026-08-13
PUBMEDDynamic Tuning of MSC-Based Scaffolds for Neurological Protection After Brain or CNS Injury.2026-07-13
PUBMEDPathophysiology and pharmacological management for sleep problems in Parkinson's disease.2026-07-01
PUBMEDComparative Analysis of Ultra-Low Versus Hydrogel Growing Conditions for Patient-Derived Glioma Organoids.2026-06-22
PUBMEDPsychological Aspects and Mental Health Risks in Children and Adolescents with Congenital Heart Defects-A Systematic Review.2026-04-23
Sources and provenance
ClinicalTrials.gov provides NCT evidence. PubMed/NCBI and OpenAlex provide research metadata. OpenAlex links institutions. World Bank indicators are included only when an explicit source row and year exist. NeuroRisk transformations add normalization, ranking and graph connections.
Limitations
Indexed corpus counts are not guaranteed exhaustive global totals. Scores are comparative decision-support signals. This report is not medical advice, regulatory advice, patent clearance, an investment recommendation or a guarantee of outcome.